CHB — Global X China Biotech Innovation ETF

CHB Fund Overview

CHB — Global X China Biotech Innovation ETF is a US ETF managed by Global X Funds, categorised as Emerging Markets Small Cap Growth Thematic Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.

• Type: US ETF
• Manager: Global X Funds
• Category: Emerging Markets Small Cap Growth Thematic Equity
• Assets under management: $2.30M
• 1-year return: -11.7%
• Ticker: CHB
• SEC CIK: 0001432353
• SEC series ID: S000069671
• Share class ID: C000222222

CHB Investment Objective and Strategy

Global X China Biotech Innovation ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Global X Funds.

Investment objective

"The Global X China Biotech Innovation ETF (""Fund"") seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index (""Underlying Index"")."

Principal investment strategy

"The Fund invests at least 80% of its total assets, plus borrowings for investment purposes (if any), in the securities of the Solactive China Biotech Innovation Index (""Underlying Index"") and in American Depositary Receipts (""ADRs"") and Global Depositary Receipts (""GDRs"") based on the securities in the Underlying Index. The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Underlying Index is designed to provide exposure to exchange-listed companies that are directly involved in Chinas biotechnology industry. The securities eligible for inclusion in the Underlying Index include: H-Shares (securities of companies incorporated in China that are denominated in Hong Kong Dollars and listed on the Hong Kong Stock Exchange (the ""HKSE"")); Red Chips (securities of companies with a majority of their business operations in mainland China and that are controlled by the national government or local governments of China, traded on the HKSE in Hong Kong dollars); P-Chips (securities of companies with the majority of their business operations in mainland China and controlled by individuals in China, but that are incorporated outside of China); A-Shares (securities of companies incorporated in mainland China that trade on Chinese exchanges in renminbi) that are accessible through the Shanghai-Hong Kong Stock Connect program (""Shanghai Connect"") or the Shenzhen-Hong Kong Stock Connect program (""Shenzhen Connect"", and together with Shanghai Connect, ""Stock Connect Programs""); and Foreign listings such as American Depository Receipts (""ADRs"").

The Stock Connect Programs are securities trading and clearing programs that aim to achieve mutual stock market access between China and Hong Kong. Under the Stock Connect Programs, the Fund's trading of eligible A-Shares listed on the Shanghai Stock Exchange (""SSE"") or Shenzhen Stock Exchange (""SZSE""), as applicable, would be effectuated through its Hong Kong brokers. Trading through the Stock Connect Programs is subject to a daily quota, which limits the maximum net purchases under Stock Connect Programs each day, and as such, buy orders for A-Shares would be rejected once the daily quota is exceeded (although the Fund will be permitted to sell A-Shares regardless of the daily quota balance). The daily quota is not specific to the Fund. From time to time, other stock exchanges in China may participate in Stock Connect Programs, and A-Shares listed and traded on such other stock exchanges and accessible through Stock Connect Programs may be added to the Underlying Index, as determined by Solactive AG, the provider of the Underlying Index (the Index Provider).

In constructing the Underlying Index, the Index Provider utilizes FactSet Industry classifications to identify companies that are directly involved in the biotechnology industry. Only those securities classified in the biotechnology industry according to FactSet as of each rebalance date are eligible for inclusion in the Underlying Index. To be a part of the eligible universe of the Underlying Index, certain minimum market capitalization and liquidity criteria, as defined by the Index Provider, must be met. As of January 31, 2023, companies must have a minimum free float market capitalization of $200 million and a minimum average daily turnover for the last 6 months greater than or equal to $2 million in order to be eligible for inclusion in the Underlying Index. The Underlying Index is weighted according to a modified capitalization weighting methodology and is reconstituted and re-weighted semi-annually.

Modified capitalization weighting seeks to weight constituents primarily based on market capitalization, but subject to caps on the weights of the individual securities. During each rebalance, the maximum weight of a company is capped at 8%, the aggregate weight of companies with a weight greater than or equal to 5% is capped at 40%, all remaining companies are capped at a weight of 4.5%, and all constituents are subject to a minimum weight of 0.3%. Generally speaking, this approach will limit the amount of concentration in the largest market capitalization companies and increase company-level diversification. The Underlying Index may include large-, mid- or small-capitalization companies, and components primarily include health care companies. As of January 31, 2023, the Underlying Index had 26 constituents.

The Fund's investment objective and Underlying Index may be changed without shareholder approval. The Underlying Index is sponsored by the Index Provider, which is an organization that is independent of, and unaffiliated with, the Fund and Global X Management Company LLC, the investment adviser for the Fund (""Adviser""). The Index Provider determines the relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index. The Adviser uses a ""passive"" or indexing approach to try to achieve the Fund's investment objective. Unlike many investment companies, the Fund does not try to outperform the Underlying Index and does not seek temporary defensive positions when markets decline or appear overvalued. The Fund generally will use a replication strategy.

A replication strategy is an indexing strategy that involves investing in the securities of the Underlying Index in approximately the same proportions as in the Underlying Index. However, the Fund may utilize a representative sampling strategy with respect to the Underlying Index when a replication strategy might be detrimental or disadvantageous to shareholders, such as when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to replicate the Underlying Index, in instances in which a security in the Underlying Index becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations (such as tax diversification requirements) that apply to the Fund but not the Underlying Index. The Adviser expects that, over time, the correlation between the Fund's performance and that of the Underlying Index, before fees and expenses, will exceed 95%.

A correlation percentage of 100% would indicate perfect correlation. If the Fund uses a replication strategy, it can be expected to have greater correlation to the Underlying Index than if it uses a representative sampling strategy. The Fund concentrates its investments (i.e., holds 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. As of January 31, 2023, the Underlying Index was concentrated in the Underlying Index was concentrated in the biotechnology industry and had significant exposure to the health care sector."

CHB Holdings

Top 10 holdings of Global X China Biotech Innovation ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.

View all CHB holdings

CHB Portfolio Allocation

Asset-class allocation of Global X China Biotech Innovation ETF by percentage of net assets, from the latest SEC N-PORT filing.

CHB Performance

Total returns for CHB (as of 2026-10-01), from SEC filings.

CHB Risk Information

Risk metrics for CHB, derived from monthly returns in SEC filings.

• 1-year volatility (annualised): 23.1%

CHB Costs and Fees

CHB costs about $65 per $10,000 invested per year in fund expenses.

• Net expense ratio: 0.65%
• Gross expense ratio: 0.65%
• Portfolio turnover: 41%
• Brokerage commissions: 5.50 bps of average net assets (SEC N-CEN)

CHB Cashflows

Over the 12 months to 2023-11, Global X China Biotech Innovation ETF had net outflows of $15.91K, from monthly SEC N-PORT filings.

CHB Debt Constituents

No individual debt constituents are reported in Global X China Biotech Innovation ETF's latest SEC N-PORT filing.

CHB Prospectus and SEC Filings

Official Global X China Biotech Innovation ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.

• Prospectus (485BPOS) — filed 2022-03-24
• Prospectus (485BPOS) — filed 2021-03-24
• Prospectus supplement (497) — filed 2023-03-31
• Portfolio holdings (N-PORT) — filed 2024-01-29
• Portfolio holdings (N-PORT) — filed 2023-10-30
• Portfolio holdings (N-PORT) — filed 2023-07-26
• Annual census (N-CEN) — filed 2024-02-13
• Annual census (N-CEN) — filed 2023-02-10

Related Funds

Related funds tracked on ABC INVEST:

• Global X U.S. Infrastructure Development ETF (PAVE)
• Global X Future Analytics Tech ETF (AIQ)
• Global X NASDAQ 100 Covered Call ETF (QYLD)
• Global X Defense Tech ETF (SHLD)
• Global X Copper Miners ETF (COPX)

Data Sources

ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.